Stock JAZZ JAZZ PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
109.6 USD -3.09% Intraday chart for Jazz Pharmaceuticals plc -0.35% -10.87%
May. 07 Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing MT
May. 03 UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8,445 9,196 7,831 10,031 7,744 6,911 - -
Enterprise Value (EV) 1 9,415 10,233 13,290 14,874 11,830 10,461 8,963 8,235
P/E ratio 16.4 x 39.1 x -23.1 x -44.5 x 20.2 x 18.6 x 12 x 12.7 x
Yield - - - - - - - -
Capitalization / Revenue 3.91 x 3.89 x 2.53 x 2.74 x 2.02 x 1.7 x 1.59 x 1.51 x
EV / Revenue 4.36 x 4.33 x 4.29 x 4.06 x 3.09 x 2.58 x 2.06 x 1.8 x
EV / EBITDA 8.43 x 11.1 x 6.72 x 11.1 x 7.04 x 6 x 4.45 x 3.74 x
EV / FCF 12.8 x 11.6 x 17.7 x 12 x - 8.61 x 6.43 x 5.38 x
FCF Yield 7.82% 8.65% 5.65% 8.36% - 11.6% 15.5% 18.6%
Price to Book 2.69 x 2.53 x 1.98 x 3.26 x - 1.6 x 1.34 x 1.12 x
Nbr of stocks (in thousands) 56,573 55,714 61,470 62,966 62,957 63,040 - -
Reference price 2 149.3 165.0 127.4 159.3 123.0 109.6 109.6 109.6
Announcement Date 2/25/20 2/23/21 3/1/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,162 2,364 3,094 3,659 3,834 4,054 4,357 4,572
EBITDA 1 1,117 917.9 1,978 1,338 1,681 1,745 2,016 2,203
EBIT 1 1,102 899.3 1,425 1,307 1,650 1,713 1,888 1,974
Operating Margin 50.98% 38.05% 46.07% 35.73% 43.04% 42.26% 43.35% 43.18%
Earnings before Tax (EBT) 1 454.3 275.1 -112.8 -372.8 297.9 414.4 633.6 655.2
Net income 1 523.4 238.6 -329.7 -224.1 414.8 430.5 618.7 632
Net margin 24.21% 10.1% -10.65% -6.12% 10.82% 10.62% 14.2% 13.82%
EPS 2 9.090 4.220 -5.520 -3.580 6.100 5.887 9.116 8.629
Free Cash Flow 1 736.3 884.6 750.9 1,243 - 1,214 1,394 1,531
FCF margin 34.06% 37.43% 24.27% 33.97% - 29.96% 31.99% 33.48%
FCF Conversion (EBITDA) 65.89% 96.37% 37.96% 92.91% - 69.6% 69.14% 69.49%
FCF Conversion (Net income) 140.68% 370.74% - - - 282.09% 225.24% 242.19%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/25/20 2/23/21 3/1/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 896.7 813.7 932.9 940.7 972.1 892.8 957.3 972.1 1,012 902 1,005 1,044 1,095 980.9 1,047
EBITDA 1 561.1 410.1 418.6 509.9 31.21 405 435.4 421.9 428.7 345.2 430.7 465.9 520.8 - -
EBIT 1 396.5 402.5 410.8 502.3 23.87 397.4 427.9 414.2 421.1 317.2 428.3 467.6 502.1 371.7 467
Operating Margin 44.21% 49.47% 44.04% 53.4% 2.46% 44.51% 44.69% 42.61% 41.61% 35.16% 42.64% 44.79% 45.84% 37.89% 44.61%
Earnings before Tax (EBT) 1 -44.83 6.325 21.01 -60.13 -340 55.1 81.78 99.52 61.53 -1.602 96.82 134 181.9 115.8 141.5
Net income 1 -35.35 1.647 34.66 -19.65 -240.7 69.42 104.4 146.8 94.15 -14.62 106.7 152.3 154.9 118.1 143.5
Net margin -3.94% 0.2% 3.72% -2.09% -24.76% 7.78% 10.91% 15.1% 9.3% -1.62% 10.62% 14.59% 14.14% 12.04% 13.7%
EPS 2 -0.5700 0.0300 0.5500 -0.3100 -3.820 1.040 1.520 2.140 1.420 -0.2300 1.447 2.115 2.092 1.670 2.030
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 3/1/22 5/4/22 8/3/22 11/9/22 3/1/23 5/10/23 8/9/23 11/8/23 2/28/24 5/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 970 1,037 5,458 4,843 4,087 3,550 2,052 1,324
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.868 x 1.13 x 2.76 x 3.62 x 2.431 x 2.034 x 1.018 x 0.6012 x
Free Cash Flow 1 736 885 751 1,243 - 1,214 1,394 1,531
ROE (net income / shareholders' equity) 31.8% 20.8% 26% 26.5% 38% 29.5% 29.8% 26.4%
ROA (Net income/ Total Assets) 9.74% 11.7% 10.5% 8.07% 3.73% 7.58% 7.23% 6.45%
Assets 1 5,371 2,046 -3,127 -2,776 11,114 5,679 8,561 9,803
Book Value Per Share 2 55.40 65.20 64.30 48.80 - 68.60 82.10 97.50
Cash Flow per Share 2 13.50 15.90 13.00 20.30 15.20 20.00 19.70 19.50
Capex 1 40.1 15 27.6 29 - 32 32.3 34.1
Capex / Sales 1.86% 0.63% 0.89% 0.79% - 0.79% 0.74% 0.75%
Announcement Date 2/25/20 2/23/21 3/1/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jazz Pharmaceuticals plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
109.6 USD
Average target price
182 USD
Spread / Average Target
+66.01%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
JAZZ PHARMACEUTICALS PLC Stock Jazz Pharmaceuticals plc
-10.87% 6.91B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. Financials Jazz Pharmaceuticals plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW